Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

IGM Biosciences Inc (IGMS) USD0.01

Sell:$73.64 Buy:$73.80 Change: $1.18 (1.58%)
Market closed |  Prices as at close on 20 September 2021 | Switch to live prices |
Sell:$73.64
Buy:$73.80
Change: $1.18 (1.58%)
Market closed |  Prices as at close on 20 September 2021 | Switch to live prices |
Sell:$73.64
Buy:$73.80
Change: $1.18 (1.58%)
Market closed |  Prices as at close on 20 September 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

IGM Biosciences Inc is a biotechnology company engaged in the development of engineered IgM antibodies for the treatment of cancer patients. It has developed IgM antibody technology platform that is particularly well suited for developing T cell engagers, receptor cross-linking agonists and targeted cytokines. The Company’s lead product candidates are IGM-2323: CD20 x CD3 and Death Receptor 5 (DR5). Its IgM platform enables to create a broad pipeline of product candidates. The Company is also conducting research and discovery programs on CD3 T cell engaging antibodies; T cell stimulating antibodies, including antibodies that target T cell stimulatory members of the TNFrSF; and antibodies that are intended to deliver IL-15 to a target to enhance cancer immune responses while limiting systemic toxicity. Its product pipelines also include CD20 x CD3, CD123 x CD3, CD38 x CD3, solid tumor target x CD3 programs, OX40 and glucocorticoid-induced TNFr-related protein (GITR).

Contact details

Address:
325 E Middlefield Rd
MOUNTAIN VIEW
94043-4003
United States
Telephone:
+1 (650) 9657873
Website:
igmbio.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
IGMS
ISIN:
US4495851085
Market cap:
$2.40 billion
Shares in issue:
32.06 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Michael Loberg
    Independent Chairman of the Board
  • Fred Schwarzer
    President, Chief Executive Officer, Director
  • Misbah Tahir
    Chief Financial Officer
  • Bruce Keyt
    Chief Scientific Officer
  • Lisa Decker
    Chief Business Officer
  • George Gauthier
    Chief Commercial Officer
  • Chris Takimoto
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.